Comparative Pharmacology
Head-to-head clinical analysis: FAYOSIM versus X TROZINE L A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FAYOSIM versus X TROZINE L A.
FAYOSIM vs X-TROZINE L.A.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FAYOSIM (plecanatide) is a guanylate cyclase-C (GC-C) agonist. It binds to GC-C receptors on the luminal surface of intestinal epithelial cells, activating the receptor and increasing intracellular cyclic guanosine monophosphate (cGMP) levels. Elevated cGMP stimulates chloride and bicarbonate secretion into the intestinal lumen, enhancing fluid secretion and accelerating gastrointestinal transit, thereby promoting bowel movements.
X-TROZINE L.A. is a piperazine derivative that acts as a centrally acting alpha-2 adrenergic agonist, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and lowered blood pressure.
10 mg orally once daily
250 mg orally once daily. May be increased to 500 mg once daily if needed.
None Documented
None Documented
12-16 hours in healthy adults; prolonged to 20-30 hours in moderate renal impairment (CrCl <50 mL/min) requiring dose adjustment.
12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
Primarily renal elimination, 80% unchanged drug in urine; 15% biliary/fecal; 5% metabolized.
Primarily renal (70-80% as unchanged drug), with 20-30% fecal via biliary excretion.
Category C
Category C
Antihistamine
Antihistamine